Teva’s proposed opioid settlement could cost drugmaker pennies on the dollar

NEW YORK/BOSTON (Reuters) - Teva Pharmaceutical Industries Ltd's proposed $23 billion (£17.85 billion) drug giveaway to settle thousands of U.S. opioid lawsuits will likely cost the company a fraction of that figure due to how it has valued those medicines, according to a Reuters review of pricing data and industry analysts.When Teva announced the value of the donated medicine - a generic version of opioid addiction treatment Suboxone - it based the figure on the drug's list price, which does..